By Bernadette Toner

Epistem last week announced that it has signed a three-year collaboration with Sanofi-Aventis to use its proprietary biomarker discovery technology as part of the pharmaceutical firm's oncology programs.

The agreement, worth up to $4 million, will cover preclinical, ex vivo, and clinical studies and is aimed at providing Sanofi-Aventis with gene expression biomarkers that will identify patient response to drugs.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.

The new Riken president outlines some of his plans for the institute.